IMPACT THERAP-B (07630) Defies Market Trend with Over 15% Surge; Senaparib Approved in EU for First-Line Maintenance Treatment Across All Ovarian Cancer Patients

Stock News11-19 10:30

IMPACT THERAP-B (07630) bucked the broader market trend, surging more than 15%. As of press time, the stock was up 11.85% at HK$9.295, with a turnover of HK$53.443 million.

On the news front, on November 17, IMPACT THERAP-B announced that its independently developed innovative drug Senaparib (Paishuning®, overseas brand name Sepalna®) has officially received the final decision from the European Commission, approving its use for maintenance treatment of advanced epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.

This approval was formally granted following the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency. Senaparib thus becomes the first China-originated PARP inhibitor approved in the EU for first-line maintenance treatment across the entire population of advanced ovarian cancer patients, marking another breakthrough for a domestically developed targeted innovative drug for ovarian cancer in the European market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment